Increasing Buprenorphine Access in Community Pharmacies Post-Test | August 30, 2023-2026

Which of the following statements is true regarding buprenorphine for OUD.*
- A special x-waiver is required by the prescribing clinician.
- Buprenorphine may only be utilized in opioid treatment programs (OTPs) that dispense methadone.
- Buprenorphine reduces overdose risk and engages patients in treatment.
- Buprenorphine replaces one opioid with another.
A pregnant patient cannot receive 32 mg of Suboxone daily for the treatment of OUD because it exceeds the FDA labeled dosing and will harm the fetus.*
- True
- False
Which of the following statements is true regarding patients taking buprenorphine who have pain?*
- Daily OUD doses of buprenorphine provide analgesia all day long.
- If buprenorphine is used as an analgesic and for treatment of OUD, the doses should be divided throughout the day (e.g., TID).
- Only non-pharmacologic options should be used to manage pain when patients take buprenorphine.
- Patients should stop buprenorphine, treat acute pain, and then start buprenorphine again once pain has resolved.
All patients with OUD should be prescribed naloxone.*
- True
- False
A patient presents to your pharmacy with a new prescription for Suboxone 8/2 mg film – 2 films daily (total 16 mg/day). What do you do?*
- Decline to fill the prescription because it will put you over your cap on buprenorphine prescriptions.
- Decline to fill it because you don’t want the DEA to investigate your pharmacy.
- Decline to fill it because you don’t have time to submit the prior authorization for Delaware Medicaid.
- Fill the prescription because it is a life-saving medication.

Increasing Buprenorphine Access in Community Pharmacies Post-Test | August 30, 2023-2026

Step 1 of 2

Join our newsletter